Good systemic control of blood sugar, hypertension, dyslipidemia and renal function
Timely treatment involving intra-vitreal anti-VEGF injections, laser photocoagulation when appropriate and surgical intervention when necessary
To have access to full article that these tools were developed for, please subscribe. The cost to subscribe is $80 USD per year and you will gain full access to all the premium content on www.healthplexus.net, an educational portal, that hosts 1000s of clinical reviews, case studies, educational visual aids and more as well as within the mobile app.
Chris Hudson, PhD, MCOptom, FAAO, Professor, School of Optometry, University of Waterloo, Waterloo, ON; Associate Professor, Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON; Director of Retinal Research, University Health Network, Toronto, ON; scientist, Toronto Western Research Institute, Toronto, ON.
Diabetic retinopathy (DR) remains the leading cause of vision loss and blindness in people of working age, in spite of the fact that current treatments are effective. Vision loss occurs in DR due to the development of maculopathy, especially diabetic macular edema, and due to proliferative diabetic retinopathy. Vision loss due to DR is preventable with the appropriate monitoring and timely treatment. Improved patient and health professional, education to encourage tight control of blood glucose and other systemic factors, and the establishment of readily available and appropriately timed eye examinations are necessary steps to further reduce visual impairment of people with diabetes. Key words: diabetic retinopathy, vision loss, macular edema, neovascularization, laser photocoagulation.
